journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/28715579/use-of-neoadjuvant-platinum-the-ongoing-conundrum
#1
Hope S Rugo, Karen Gelmon
No abstract text is available yet for this article.
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28715578/adverse-pathologic-findings-for-men-electing-immediate-radical-prostatectomy-defining-a-favorable-intermediate-risk-group
#2
Hiten D Patel, Jeffrey J Tosoian, H Ballentine Carter, Jonathan I Epstein
Importance: Active surveillance is recommended for patients with very low-risk (VLR) and low-risk (LR) prostate cancer. Despite controversy, recent clinical guidelines state surveillance may be considered for men with low-volume intermediate-risk (LVIR) disease. Objective: To compare rates of adverse pathologic findings among VLR, LR, and LVIR men electing immediate radical prostatectomy and evaluate criteria to define if a favorable intermediate-risk group minimizing risk exists...
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28715568/overestimating-the-benefit-of-cancer-drugs
#3
Vinay Prasad
No abstract text is available yet for this article.
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28715567/small-cell-large-impact
#4
Amishi Bajaj
No abstract text is available yet for this article.
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28715557/overestimating-the-benefit-of-cancer-drugs-reply
#5
Sebastian Salas-Vega, Elias Mossialos
No abstract text is available yet for this article.
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28715540/predictors-of-hand-foot-syndrome-and-pyridoxine-for-prevention-of-capecitabine-induced-hand-foot-syndrome-a-randomized-clinical-trial
#6
Yoon-Sim Yap, Li-Lian Kwok, Nicholas Syn, Wen Yee Chay, John Whay Kuang Chia, Chee Kian Tham, Nan Soon Wong, Soo Kien Lo, Rebecca Alexandra Dent, Sili Tan, Zuan Yu Mok, King Xin Koh, Han Chong Toh, Wen Hsin Koo, Marie Loh, Raymond Chee Hui Ng, Su Pin Choo, Richie Chuan Teck Soong
Importance: Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective: To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. Design, Setting, and Participants: This single-center, randomized double-blind, placebo-controlled phase 3 trial conducted at National Cancer Centre Singapore assessed whether oral pyridoxine could prevent the onset of grade 2 or higher HFS in 210 patients scheduled to receive single-agent capecitabine chemotherapy for breast, colorectal, and other cancers...
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28715532/germline-mutation-status-pathological-complete-response-and-disease-free-survival-in-triple-negative-breast-cancer-secondary-analysis-of-the-geparsixto-randomized-clinical-trial
#7
Eric Hahnen, Bianca Lederer, Jan Hauke, Sibylle Loibl, Sandra Kröber, Andreas Schneeweiss, Carsten Denkert, Peter A Fasching, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Sherko Kümmel, Christian Schem, Guido Neidhardt, Jens Huober, Kerstin Rhiem, Serban Costa, Janine Altmüller, Claus Hanusch, Holger Thiele, Volkmar Müller, Peter Nürnberg, Thomas Karn, Valentina Nekljudova, Michael Untch, Gunter von Minckwitz, Rita K Schmutzler
Importance: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germline mutation status affects treatment outcome remains elusive. Objective: To determine whether BRCA1 and BRCA2 germline mutation status affects therapy response in patients with TNBC...
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28687838/development-and-validation-of-an-individualized-immune-prognostic-signature-in-early-stage-nonsquamous-non-small-cell-lung-cancer
#8
Bailiang Li, Yi Cui, Maximilian Diehn, Ruijiang Li
Importance: The prevalence of early-stage non-small cell lung cancer (NSCLC) is expected to increase with recent implementation of annual screening programs. Reliable prognostic biomarkers are needed to identify patients at a high risk for recurrence to guide adjuvant therapy. Objective: To develop a robust, individualized immune signature that can estimate prognosis in patients with early-stage nonsquamous NSCLC. Design, Setting, and Participants: This retrospective study analyzed the gene expression profiles of frozen tumor tissue samples from 19 public NSCLC cohorts, including 18 microarray data sets and 1 RNA-Seq data set for The Cancer Genome Atlas (TCGA) lung adenocarcinoma cohort...
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28687837/mutation-frequencies-in-patients-with-early-onset-colorectal-cancer
#9
Florentia Fostira, Ioannis Papaconstantinou
No abstract text is available yet for this article.
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28687834/mutation-frequencies-in-patients-with-early-onset-colorectal-cancer
#10
Andrew D Beggs
No abstract text is available yet for this article.
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28687833/mutation-frequencies-in-patients-with-early-onset-colorectal-cancer
#11
Steven A Narod, Mohammad Akbari
No abstract text is available yet for this article.
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28687830/effect-of-the-addition-of-cetuximab-to-paclitaxel-cisplatin-and-radiation-therapy-for-patients-with-esophageal-cancer-the-nrg-oncology-rtog-0436-phase-3-randomized-clinical-trial
#12
Mohan Suntharalingam, Kathryn Winter, David Ilson, Adam P Dicker, Lisa Kachnic, André Konski, A Bapsi Chakravarthy, Christopher J Anker, Harish Thakrar, Naomi Horiba, Ajay Dubey, Joel S Greenberger, Adam Raben, Jeffrey Giguere, Kevin Roof, Gregory Videtic, Jondavid Pollock, Howard Safran, Christopher H Crane
Importance: The role of epidermal growth factor receptor (EGFR) inhibition in chemoradation strategies in the nonoperative treatment of patients with esophageal cancer remains uncertain. Objective: To evaluate the benefit of cetuximab added to concurrent chemoradiation therapy for patients undergoing nonoperative treatment of esophageal carcinoma. Design, Setting, and Participants: A National Cancer Institute (NCI) sponsored, multicenter, phase 3, randomized clinical trial open to patients with biopsy-proven carcinoma of the esophagus...
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28687829/mutation-frequencies-in-patients-with-early-onset-colorectal-cancer
#13
Steven Sorscher
No abstract text is available yet for this article.
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28687825/conflict-of-interest-conflicting-interests-and-effective-collaboration-between-academia-and-industry-on-preclinical-and-clinical-cancer-research
#14
Mace L Rothenberg, David H Johnson
No abstract text is available yet for this article.
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28687820/mutation-frequencies-in-patients-with-early-onset-colorectal-cancer-reply
#15
Rachel Pearlman, Albert de la Chapelle, Heather Hampel
No abstract text is available yet for this article.
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28662235/use-of-pd-1-targeting-macrophage-infiltration-and-ido-pathway-activation-in-sarcomas-a-phase-2-clinical-trial
#16
Maud Toulmonde, Nicolas Penel, Julien Adam, Christine Chevreau, Jean-Yves Blay, Axel Le Cesne, Emmanuelle Bompas, Sophie Piperno-Neumann, Sophie Cousin, Thomas Grellety, Thomas Ryckewaert, Alban Bessede, François Ghiringhelli, Marina Pulido, Antoine Italiano
Importance: There is a strong rationale for treating sarcomas with immunotherapy. Objective: To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas. Design, Setting, and Participants: This was an open-label, multicenter, phase 2 study of 4 cohorts of patients with advanced soft-tissue sarcoma (STS), including leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), other sarcomas (others), and gastrointestinal stromal tumor (GIST)...
June 29, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28662232/nivolumab-for-patients-with-advanced-melanoma-treated-beyond-progression-analysis-of-2-phase-3-clinical-trials
#17
Georgina V Long, Jeffrey S Weber, James Larkin, Victoria Atkinson, Jean-Jacques Grob, Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Ivan Márquez-Rodas, Catriona McNeil, Henrik Schmidt, Karen Briscoe, Jean-François Baurain, F Stephen Hodi, Jedd D Wolchok
Importance: Immune checkpoint inhibitors have demonstrated atypical response patterns, which may not be fully captured by conventional response criteria. There is a need to better understand the potential benefit of continued immune checkpoint inhibition beyond progression. Objective: To evaluate the safety and potential benefit of nivolumab (anti-programmed cell death receptor 1) monotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST) v1.1-defined progression...
June 29, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28662228/treatment-beyond-progression-with-immune-checkpoint-inhibitors-known-unknowns
#18
Gideon M Blumenthal, Marc R Theoret, Richard Pazdur
No abstract text is available yet for this article.
June 29, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28662223/exclusion-of-kaposi-sarcoma-from-analysis-of-cancer-burden-reply
#19
Christina Fitzmaurice, Mohsen Naghavi
No abstract text is available yet for this article.
June 29, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28662222/use-of-molecular-tools-to-identify-patients-with-indolent-breast-cancers-with-ultralow-risk-over-2-decades
#20
Laura J Esserman, Christina Yau, Carlie K Thompson, Laura J van 't Veer, Alexander D Borowsky, Katherine A Hoadley, Nicholas P Tobin, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Christopher C Benz, Linda S Lindström
Importance: The frequency of cancers with indolent behavior has increased with screening. Better tools to identify indolent tumors are needed to avoid overtreatment. Objective: To determine if a multigene classifier is associated with indolent behavior of invasive breast cancers in women followed for 2 decades. Design, Setting, and Participants: This is a secondary analysis of a randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up...
June 29, 2017: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"